An epithelial cell adhesion molecule- and CD3-bispecific antibody plus activated T-cells can eradicate chemoresistant cancer stem-like pancreatic carcinoma cells in vitro

Anticancer Research

Volumn 34, Issue 8, 2014, Pages 4509-4520

  Umebayashi, Masayo ^a   Kiyota, Akifumi ^a   Koya, Norihiro ^a   Tanaka, Hiroto ^a   Onishi, Hideya ^b   Katano, Mitsuo ^b   Morisaki, Takashi ^a  

^a Fukuoka General Cancer Clinic   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Cancer stem like cells; Catumaxomab; Chemoresistance; Cytokine activated T cells; EpCAM

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; CATUMAXOMAB; CD3 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; GEMCITABINE; HERMES ANTIGEN; BISPECIFIC ANTIBODY; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; TUMOR ANTIGEN;

ADULT; ANTIBODY DEPENDENT LYMPHOCYTOTOXICITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER STEM CELL; CELL HYPOXIA; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; MALE; MIDDLE AGED; PANCREAS CARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR INVASION; ARTICLE; CANCER STEM-LIKE CELLS; CHEMORESISTANCE; CYTOKINE-ACTIVATED T-CELLS; DRUG EFFECT; DRUG RESISTANCE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PANCREAS TUMOR; TUMOR CELL LINE;

CANCER STEM-LIKE CELLS; CATUMAXOMAB; CHEMORESISTANCE; CYTOKINE-ACTIVATED T-CELLS; EPCAM;

ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; LYMPHOCYTE ACTIVATION; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; T-LYMPHOCYTES;

EID: 84908695868     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Sergeant G, Vankelecom H, Gremeaux L and Topal B: Role of cancer stem cells in pancreatic ductal adenocarcinoma. Nat Rev Clin Oncol 6: 580-586, 2009.
3. Visvader JE: Cells of origin in cancer. Nature 469: 314-322, 2011.
4. Li Y and Laterra J: Cancer stem cells: distinct entities or dynamically regulated phenotypes? Cancer Res 72: 576-580, 2012.
5. Singh A and Settleman J: EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29: 4741-4751, 2010.
6. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G 2nd, Samuel S, Kim MP, Lim SJ and Ellis LM: Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 69: 1951-1957, 2009.
7. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J and Weinberg RA: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715, 2008.
8. Deonarain MP, Kousparou CA and Epenetos AA: Antibodies targeting cancer stem cells: a new paradigm in immunotherapy? MAbs 1: 12-25, 2009.
9. Armstrong A, and Eck SL: EpCAM: A new therapeutic target for an old cancer antigen. Cancer Biol Ther 2: 320-326, 2003.
10. Munz M, Baeuerle PA and Gires O: The emerging role of EpCAM in cancer and stem cell signalling. Cancer Res 69: 5627-5629, 2009.
11. Jäger M, Schoberth A, Ruf P, Hess J, Hennig M, Schmalfeldt B, Wimberger P, Ströhlein M, Theissen B, Heiss MM and Lindhofer H: Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAMxanti-CD3). Cancer Res 72: 24-32, 2012.
12. Cioffi M, Dorado J, Baeuerle PA and Heeschen C: EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res 18: 465-474, 2012.
13. Morisaki T, Onishi H and Katano M: Cancer immunotherapy using NKG2D and DNAM-1 systems. Anticancer Res 32: 2241-2247, 2012.
14. Ullrich E, Koch J, Cerwenka A and Steinle A: New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunology 2: 10,e26097, 2013.
15. Disis ML, Bernhard H, Jaffee EM: Use of tumor-responsive T cells as cancer treatment. Lancet 373: 673-683, 2009.
16. Wang X, Cai J, Zhong H, Denham SA and Terasaki PI: Screening of high cytotoxic tumour killer cells using a sensitive adherent target detachment assay. J Immunol Methods 295: 57-65, 2004.
17. Zhou Q, Guo AL, Xu CR, An SJ, Wang Z, Yang SQ and Wu YL: A dendritic cell-based tumour vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro. Clin Exp Immunol 153: 392-400, 2008.
18. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU and Gallick GE: Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 14: 3629-3637, 2007.
19. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW, Suri P and Wicha MS: Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 66: 6063-6071, 2006.
20. Giovannetti E, Mey V, Danesi R, Mosca I and Del Tacca M: Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 10: 2936-2943, 2004.
21. Baeuerle PA and Gires O: EpCAM (CD326) finding its role in cancer. Br J Cancer 96: 417-423, 2007.
22. Patriarca C, Macchi RM, Marschner AK and Mellstedt H: Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev 38: 68-75, 2012.
23. Imrich S and Hachmeister M, Gires O: EpCAM and its potential role in tumor-initiating cells. Cell Adh Migr 6: 30-38, 2012.
24. Martowicz A, Spizzo G, Gastl G and Untergasser G: Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines. BMC Cancer 12: 501, 2012.
25. Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J, Zhu H, Thompson EW, Quinn MA, Findlay JK and Ahmed N: Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One 7: e46858, 2012.
26. Guo C, Liu H, Zhang BH, Cadaneanu RM, Mayle AM and Garraway IP: EpCAM, CD44, and CD49f distinguish sphere-forming human prostate basal cells from a subpopulation with predominant tubule initiation capability. PLoS One 7: e34219, 2012.
27. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DEand Rosenberg SA: Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26: 5233-5239, 2008.
28. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DEand Dudley ME: Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17: 4550-4557, 2011.
29. Morisaki T, Umebayashi M, Kiyota A, Koya N, Tanaka H, Onishi H and Katano M: Combining cetuximab with killer lymphocytes synergistically inhibits human cholangiocarcinoma cells in vitro. Anticancer Res 32: 2249-2256, 2012.
30. Morisaki T, Onishi H, Koya N, Kiyota A, Tanaka H, Umebayashi M, Ogino T, Nagamatsu I and Katano M: Combinatorial cytotoxicity of gemcitabine and cytokine-activated killer cells in hepartocellular carcinoma via the NKG2D-MICA/B system. Anticancer Res 31: 2505-2510, 2011.
31. Keith B and Simon MC: Hypoxia-inducible factors, stem cells, and cancer. Cell 129: 465-472, 2007.
32. Liang D, Ma Y, Liu J, Trope CG, Holm R, Nesland JM and Suo Z: The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells. BMC Cancer 12: 201, 2012.
33. Ma Y, Liang D, Liu J, Axcrona K, Kvalheim G, Stokke T, Nesland JM and Suo Z: Prostate cancer cell lines under hypoxia exhibit greater stem-like properties. PLoS One 6: e29170, 2011.